Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Luan2010 - Blood Coagulation Model (extension of Luan2007)

ABSTRACT: Mathematical model of blood coagulation. Extension of Luan2007. New reactions, e.g., the activation of platelet by thrombin through PARs, the release of ADP and TXA2 from activated platelets, platelet activation by ADP and TXA2, the intrinsic pathway reactions, were added to the model.

SUBMITTER: Matthew Roberts

PROVIDER: MODEL1806250001 | BioModels | 2018-06-25

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL1806250001?filename=Luan2010.cps	Other
	MODEL1806250001?filename=Luan2010.xml	Xml

Items per page:

1 - 2 of 2

Publications

Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.

Luan Deyan D Szlam Fania F Tanaka Kenichi A KA Barie Philip S PS Varner Jeffrey D JD

Molecular bioSystems 20100916 11

The role of mechanistic modeling and systems biology in molecular medicine remains unclear. In this study, we explored whether uncertain models could be used to understand how a network responds to a therapeutic intervention. As a proof of concept, we modeled and analyzed the response of the human coagulation cascade to recombinant factor VIIa (rFVIIa) and prothrombin (fII) addition in normal and hemophilic plasma. An ensemble of parametrically uncertain human coagulation models was developed (N ...[more]

PMID: 20844798

Similar Datasets

Anand2003 - Reactions of the Intrinsic Pathway of Blood Coagulation with Platelet Activation

Project description:Inhomogeneous blood coagulation model. Encoded model contains reactions of the intrinsic pathway with platelet activation. Initial conditions provided. Mostly an extension of Zarnitsina1996.

2018-06-13 | MODEL1806130003 | BioModels

Mechanism of abnormal coagulation induced by tigecycline in cancers

Project description:Tigecycline is a broad-spectrum active intravenous antibiotic that is also active against methicillin-resistant staphylococcus aureus. In Phase 3 and 4 clinical trials, increased all-cause mortality was observed in patients treated with tigecycline compared to patients in the control group. The reason for the increase is not yet clear. In this study, we found tigecycline could cause abnormal coagulation in tumor patients, especially in patients with hematological malignancies. The main manifestations were decreased fibrinogen and prolonged activated prothrombin time (APTT), thrombin time (TT) and D-dimer. In addition, functional studies have found that tigecycline could inhibit platelet adhesion and aggregation, and the patient's coagulation function could gradually recover after discontinuation. Gene sequencing results suggested that tigecycline could significantly regulate the expression of genes related to platelet function pathways, and could increase the incidence of single nucleotide polymorphisms and the number of alternative splices in CHO cells with tigecycline treatment. Abnormal platelet function and low numbers are common in patients with hematological malignancies. Our study could explain the mechanism of abnormal coagulation caused by tigecycline. At the same time, a warning should be given when doctors applied tigecycline to cure infections in tumor patients.

2022-06-01 | GSE198830 | GEO

Zarnitsina1996 - Reactions of the Intrinsic Pathway of Blood Coagulation

Project description:Model listing the reactions of the intrinsic pathway as listed in Zarnitsina1996. Publication model is a spatio-termporal mathematical model of blood coagulation. Model used as the example of the numerical intrinsic pathway in Braescu et al. (2011). L. Braescu, M. Leretter, T. George, New direct inhibitors and their computed effect on the dynamics of thrombin formation in blood coagulation, in: T. F. George (Ed.), Computational Studies of New Materials II, World Scientific, 2011, 173–190. doi:10.3389/fphys.2012.00266.

2018-06-14 | MODEL1806140001 | BioModels

Mitrophanov2016 - Extended Mitrophanov2011 Blood Coagulation Model (additional thrombin reactions)

Project description:Mathematical model of blood coagulation. Extended model of Mitrophanov2011 (which is an extension of Hockin2002). Additional reactions added involving thrombin. Modelling the effects of dilution and addition of recombinant factor VIIa, II, VII, IX, X, AT.

2018-06-28 | MODEL1806280001 | BioModels

Self-anticoagulant sponges for whole blood auto-transfusion and its mechanism of coagulation factor inactivation

Project description:Clinical use of intraoperative auto-transfusion requires the removal of platelets and plasma proteins due to the pump-based suction and water-soluble anticoagulant administration, which causes dilutional coagulopathy. Herein, we develop a carboxylated and sulfonated heparin-mimetic polymer-modified sponge that could spontaneously adsorb blood (1.149 kg/m-2 s-1/2) along with instantaneous anticoagulation. We demonstrate that intrinsic coagulation factors (especially XI) are inactivated by adsorption to the sponge surface, while inactivation of thrombin in the sponge-treated plasma effectively inhibits the common coagulation pathway. Benefiting from the multiple inhibitory effects of sponge on coagulation enzymes and calcium depletion, the whole blood auto-transfusion in trauma-induced hemorrhage is unprecedentedly realized. The transfusion of collected blood favors faster recovery of hemostasis compared to traditional heparinized blood in an animal model. Our work not only develops a safe and convenient approach for whole blood auto-transfusion, but also provides the mechanism of action of self-anticoagulant heparin-mimetic polymer-modified surfaces.

2023-07-23 | PXD044005 | Pride

Bouchnita2020 - Model for blood coagulation under venous flow condition

Project description:A numerical simulation model to reproduce in vitro experiments of blood coagulation in microfluidic capillaries. A reduced one-equation model of thrombin distribution from the previous model under simplifying hypotheses and used to determine the conditions of clotting initiation on the platelet count, the shear rate, and the plasma composition.

2023-04-25 | MODEL2011030003 | BioModels

Cazzaniga2014 - Blood Coagulation with Platelet Activation

Project description:Mathematical model of blood coagulation with platelet activation. Model includes factor XII, factor VIIIa fragments, meizothrombin, kallikrein, C1-inhibitor, alpha1-Antitrypsin, alpha2-Antiplasmin, fibrinogen and fibrillin.

2018-07-18 | MODEL1807180003 | BioModels

Activation of Coagulation and Proinflammatory Pathways in Thrombosis with Thrombocytopenia Syndrome and Following COVID-19 Vaccination

Project description:Thrombosis with thrombocytopenia syndrome (TTS) is an extremely rare but potentially serious adverse event following immunization with the adenovirus vector-based COVID-19 vaccines Ad26.COV2.S (Janssen / Johnson & Johnson) or ChAdOx1 (AstraZeneca). However, no cases of TTS have been reported in over 1.5 million individuals who received a second immunization with Ad26.COV2.S in the United States, suggesting that anti-vector immunity may reduce TTS risk. Here we show robust stimulation of platelet activation and coagulation pathways and innate immune pathways in patients with TTS but only transient activation of these pathways following vaccination. We evaluated proteomic profiles in 2 patients with TTS and transcriptomic and proteomic profiles in 20 people following an initial dose and a booster dose of Ad26.COV2.S and in 14 people who received the mRNA vaccines BNT162b2 or mRNA-1273. Initial Ad26.COV2.S vaccination induced transient activation of platelet activation and coagulation pathways and innate proinflammatory pathways that resolved by day 7. TTS patients showed enhanced and sustained upregulation of these pathways, whereas a second immunization with Ad26.COV2.S or a reduced initial dose of Ad26.COV2.S resulted in lower activation of these pathways. These data provide insight into TTS pathogenesis and suggest a potential strategy for reducing TTS risk by lowering the dose of Ad26.COV2.S.

2023-10-13 | GSE220659 | GEO

miRNA expression profile in platelets after ex vivo activation

Project description:We performed microRNA sequencing (miRNA-seq) according to Illumina sequencing protocols. Platelet-rich plasma (PRP) has been obtained by centrifuging whole blood at 160 x g for 15 min at room temperature. Platelets have been activated with 3 different physiologic agonists, namely ADP (20uM), collagen (60ug/mL), or Thrombin Receptor Activating Peptide (TRAP 25uM) under continuous stirring. An aliquot of platelets has been obtained at 120 minutes following ADP, collagen and TRAP and then processed to determine miRNA expression profiles. Time 0, indicating samples before any agonist treatment, was used as baseline. Total RNA was extracted by using mirVana Paris kit (life technologies) and then was subjected to size selection library preparation and retrotranscribed. Obtained cDNA was sequenced with the Illumina HiSeq 1000 sequencer .

2015-04-27 | E-MTAB-2078 | biostudies-arrayexpress

Xu2002 - Blood Coagulation Model of Activated Factors with Platelet Activation

Project description:System of ODEs to describe the dynamics of several activated factors of blood coagulation. Publication introduces a platelet activation term for synthesis of Xa and IIa.

2018-06-13 | MODEL1806130001 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data